Search PubMedSearch

PubMed · 9822776

Editorial

Abstract

Epiluminescence microscopy (dermatoscopy) is a technique that was developed to improve the diagnostic abilities of physicians examining pigmented lesions. In experienced hands, this can provide a valuable adjunct to diagnosis of melanoma, but this technique has not been applied to nonmelanocytic skin cancer. Nonmelanocytic skin cancer represents the most common form of all types of cancer, with basal cell carcinoma being the most common cutaneous malignancy. The lead article in this issue of the Journal evaluates the use of epiluminescence microscopy in basal cell carcinomas. The conclusions suggest that diagnostic clinical acumen and biopsy still remain the definitive diagnostic tool. Nonmelanoma skin cancers are a preventable form of cancer, and thus organizations such as the American Academy of Dermatology and the Canadian Dermatology Association have invested significant time and effort in educating the public on the value of sun protection strategies. Sunlight exposure is the environmental exposure most often associated with squamous cell carcinomas of the skin. The article by Bajdik and colleagues uses a case controlled analysis to determine the risk of sunlight exposure for squamous cell carcinoma of the skin of the head and neck and the protective effect, if any, associated with wearing a hat. Their results confirm those of many other studies; that there is a strong association between squamous cell carcinoma and skin type, as well as with sunburn occurring in childhood, and with sunlight exposure during adulthood. However, there was an unusual observation in this study in that there appeared to be an increased risk of squamous cell carcinoma associated with wearing a hat. The authors speculate this may be do to bias or confounding. I would refer you to the Critical Appraisal series of last issue, Volume 3, Number 1 in which Gallagher and Lee review the methods of assessing the incident rates in nonmelanoma skin cancer and highlight some of the difficulties inherent in these studies. Bajdik and coauthors finally conclude that the use of sun protection, particularly with hats, is an unproven means of protecting against squamous cell carcinoma. In spite of this study, I feel that there is sufficient biologic rationale to remain a strong proponent of sun protection including use of hats as part of overall strategies of sun safety. While prevention should be our major goal in nonmelanoma skin cancers, surgery is the mainstay of treatment of established skin cancers. Certain skin cancers, particularly more aggressive basal-cell or squamous cell carcinomas, require MOHS surgery. This surgical technique can result in extensive defects, and repair of these defects is becoming more complex. McGeorge describes a technique, the modified rhombic flap, for optimal closure of some of these defects. In the Basic Science Series, Hosoi and coworkers study whether stress can effect the cutaneous immune response. The above article clearly demonstrates that stress can affect the cutaneous immune response by altering the cell density, intensity and morphology of the major antigen presenting cells in the skin, namely the Langerhans' cells. This gives us further support to the hypothesis that stress can indeed modulate immune function. In our Grand Rounds series, Drs. Searles, Tredget and Lin describe fatal Toxic Epidermal Necrolysis (TEN) associated with vaginal suppositories. Thankfully, TEN is a rare complication; however it can be induced by a number of agents. It is crucial to recognize these changes early since aggressive management with wound care and protection are at present our only therapeutic options.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

DN Sauder. 1998. Editorial. https://doi.org/10.1177/120347549800300201

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article